Tina NovaCo-Founder CEO Genoptix
Tina S. Nova, Ph.D., is president and CEO of the molecular diagnostics company Genoptix, a position she has held since 2000. Oncologists who specialize in blood cancers send their samples to the company, which then uses its diagnostic capabilities to rapidly determine the best course of treatment for the patient. The company has been profitable since 2007, and Forbes ranked Genoptix 15th on its 2009 list of the fastest growing companies. The company believes it can capture 15 percent of the bone marrow testing market by 2015--nearly double its current market share of 8 percent. Prior to her involvement it Genoptix, Nova was CEO of Nanogen and also did a stint as CEO of Selective Genetics. She currently serves as a member of the board of directors of Arena Pharmaceuticals and Cypress Bioscience. She holds a B.S. degree in Biological Sciences from the University of California, Irvine and a Ph.D. in Biochemistry from the University of California, Riverside.
(DIRECTOR’S NOTE: Nova, co-founder of Genoptix, sold the company in 2011 for more than $470 million dollars. She drove a top-down sports-car to the Salk, wore a yellow sport-coat, and had recently returned from a Britney Spears concert with her daughter. She is not–she tells the young women at our first “Women in Biotech at the Salk” event–what people think of when they think of a scientist. “Scientists are hot,” she adds, “the guys, too,” and the audience breaks into laughter with her. Press play, and see what else she has to say. Dr. Nova rocks. She probably changed a few career trajectories in the audience that day.)